GT Biopharma Adds University of Wisconsin–Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment
BEVERLY HILLS, Calif., March 4, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…
March 4, 2021
6 minute read
Click here to view full chart and company information.